NCT00189839View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation

PHASE3CompletedINTERVENTIONAL
Enrollment

699

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Kidney Transplantation
Interventions
DRUG

tacrolimus

Immunosuppression

Trial Locations (80)

1070

Brussels

1200

Brussels

7925

Cape Town

8001

Cape Town

28034

Madrid

Unknown

Buenos Aires

Santa Fe

Melbourne

Sydney

Westmead

Woudville South

Innsbruck

Leuven

Campinas - SP

Porto Alegre

Rio de Janeiro - RJ

San Paulo - SP

Halifax

London

Toronto

Montreal

Prague

Helsinki

Créteil

Grenoble

Le Kremlin-Bicêtre

Lille

Montpellier

Nantes

Nice

Saint-Etienne

Toulouse

Vandœuvre-lès-Nancy

Berlin

Bochum

Cologne

Erlangen

Essen

Frankfurt

Halle

Hann

München

Regensburg

Athens

Thessaloniki

Budapest

Dublin

Bari

Milan

Padua

Palermo

Pisa

Siena

Treviso

Cuernavaca Morelos

Mexico City

Maastricht

Utrecht

Oslo

Bydgoszcz

Szczecin

Durban

Pretoria

A Coruña

Badalona Barcelona

Barcelona

Córdoba

Málaga

Santander

Seville

Gothenburg

Uppsala

Zurich

Belfast

Birmingham

Coventry

Glasgow

Manchester

08025

Barcelona

08035

Barcelona

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00189839 - A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation | Biotech Hunter | Biotech Hunter